Community Physical Exercise Program in Chronic Disease

NCT ID
NCT06771024
Registry status
Not yet recruiting
Study type
Not specified in the registry data
Phase
Not applicable
Sponsor
Associação para o Desenvolvimento do Centro Académico de Investigação e Formação Biomédica do Algarv

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Enrollment: 150 participants (Estimated).

What is being studied

No interventions are listed in the registry data.

Who may be eligible

Ages
Not specified in the registry data
Sex
Not specified in the registry data
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: * Adults aged ≥50 years; * At least 2 of the following: Prior cardiovascular disease (\>12 months); High cardiovascular risk (SCORE2 or SCORE2 O.P.); Post-stroke (ischemic or hemorrhagic) with treated etiology; Type 2 Diabetes (\> 6 months, ADA); Osteoarthristis (clinical signs/symptoms, NICE); Overweight/Obesity (BMI ≥ 27 kg/m2). * Autonomous walking. * Able to provide informed consent. * Stable medications for ≥ 3 months (related to diagnoses of interest). * Physical activity below WHO recommendations. * No contraindications to exercise (cardiovascular, cerebrovascular, respiratory, musculoskeletal) according to ACSS. Exclusion Criteria: * Moderate to severe cognitive impairment - Montreal Cognitive Assessment (MoCA). * Type 2 Myocardial Infarction. * Class III or IV angina (Canadian Cardiovascular Society). * Class III or IV angina (New York Heart Association). * Uncontrolled CVD: symptomatic arrhythmias with hemodynamic compromise; severe symptomatic aortic valve stenosis; uncontrolled symptomatic heart failure; endocarditis, pericarditis, or active myocarditis; acute aortic syndrome; suspected or known dissecting aneurysm; acute systemic infections. * Pacemaker user. * Neurological disorders affecting gait. * Severe diabetes-related complications contraindicating exercise (poor metabolic control, diabetic foot, diabetic retinopathy, diabetic nephropathy, and diabetic autonomic neuropathy). * Recent use of insulin or sulphonylureas (\< 3 months). * Untreated stroke etiology: indication for revascularization; non-anticoagulated atrial fibrillation; intracranial atherosclerotic occlusive disease. * Musculoskeletal or ocular conditions preventing strength training (acute herniated disc, fractures, recent spinal surgery, glaucoma with elevated intraocular pressure). * Terminal illness. * Inability to understand basic oral or written Portuguese. * Participation in supervised dietary intervention.

Study locations

1 study location is listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: Portugal

  • Algarve, Portugal: 1

Sample of listed locations

  • Algarve Biomedical Center — Faro, Algarve, 8005-139, Portugal — Site recruitment status not specified in the registry data

Study details

Start date
October 1, 2026
Primary completion date
December 1, 2026
First posted
January 13, 2025

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT06771024
Registry last updated
September 10, 2026
QualifiedStudies registry data refreshed
September 21, 2026

View NCT06771024 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Arthritis studies | Clinical trial FAQ